Physician profile
Sunil Nagpal
NPI 1194734640
$6,193.11
in general payments reported to CMS, 2019-2025
48 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,196 · 2020: $277 · 2021: $284 · 2022: $361 · 2023: $801 · 2024: $1,066 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.62 |
| Education | $319.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,632.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $533.88 | 2019-2025 | |
| Astellas Pharma US INC | $500.58 | 2020-2025 | Padcev, Xospata, Vyloy |
| Ipsen Biopharmaceuticals, INC | $469.43 | 2019-2024 | Onivyde |
| Tempus Ai, INC | $366.96 | 2024-2025 | Xt Cdx, Tempus Pixel |
| Merck Sharp & Dohme LLC | $252.14 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $249.99 | 2019-2025 | |
| Incyte Corporation | $238.65 | 2021-2025 | Jakafi |
| Sirtex Medical INC | $225.31 | 2022-2025 | Sir-Spheres Microspheres |
| Pharmacyclics LLC, An Abbvie Company | $191.00 | 2021-2023 | Imbruvica |
| Gilead Sciences, INC. | $189.34 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $155.25 | 2019-2025 | |
| Beigene USA, INC. | $151.34 | 2020-2024 | Brukinsa |
| Eisai INC. | $86.39 | 2019 | |
| Abbvie INC. | $76.09 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $74.72 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $60.52 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Lilly USA, LLC | $57.72 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $49.01 | 2025 | Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $46.65 | 2024-2025 | Opdualag, Opdivo |
| Jazz Pharmaceuticals INC. | $45.50 | 2025 | |
| Genentech USA, INC. | $41.56 | 2024-2025 | Venclexta, Tecentriq, Perjeta |
| Stemline Therapeutics INC. | $37.95 | 2024-2025 | Orserdu |
| Celgene Corporation | $34.88 | 2019-2023 | Opdualag |
| Mirati Therapeutics, INC. | $32.88 | 2023 | Krazati |
| Recordati_rare_diseases_inc. | $30.54 | 2025 | Panhematin |
| Bayer Healthcare Pharmaceuticals INC. | $28.65 | 2020-2023 | |
| Emd Serono, INC. | $27.07 | 2024 | |
| Tersera Therapeutics LLC | $26.64 | 2025 | Zoladex |
| Beone Medicines USA, INC. | $26.05 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $25.74 | 2025 | Lynozyfic |
| Pharmaessentia USA Corporation | $20.45 | 2025 | Besremi |
| Puma Biotechnology, INC. | $20.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.14 | 2019 | |
| Caris Mpi, INC. | $19.64 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $18.68 | 2019 | |
| Deciphera Pharmaceuticals INC. | $17.21 | 2025 | Qinlock |
| Springworks Therapeutics, INC. | $17.12 | 2024 | Ogsiveo |
| Invivyd INC | $16.48 | 2025 | Pemgarda |
| Janssen Pharmaceuticals, INC | $15.46 | 2023 | Xarelto |
| Blueprint Medicines Corporation | $13.87 | 2024 | Ayvakit |
| Daiichi Sankyo INC. | $13.34 | 2024 | Enhertu |
| Dova Pharmaceuticals | $12.44 | 2020 | |
| Amgen INC. | $11.98 | 2019 | |
| Immunomedics, INC. | $11.66 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Nagpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.